Strategies for fertility preservation in young early breast cancer patients

Breast

Volumn 23, Issue 5, 2014, Pages 503-510

  Tomasi Cont, Nicoletta ^a,b   Lambertini, Matteo ^c   Hulsbosch, Sofie ^d   Peccatori, Alessandro Fedro ^b   Amant, Frederic ^d  

^a UNIVERSITY OF TURIN   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Breast cancer; Chemotherapy induced gonadotoxicity; Fertility preservation; Reproductive age

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; GOSERELIN; LETROZOLE; LUTEINIZING HORMONE; METHOTREXATE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; TRIPTORELIN;

AMENORRHEA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVOR; CRYOPRESERVATION; DISEASE FREE SURVIVAL; FEMALE INFERTILITY; FERTILITY PRESERVATION; FERTILIZATION IN VITRO; HUMAN; MULTIPLE CYCLE TREATMENT; NONHUMAN; OOCYTE RETRIEVAL; OVARIAN PRESERVATION; OVARIAN RESERVE; OVARY INSUFFICIENCY; OVERALL SURVIVAL; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY RATE; PREMATURE OVARIAN FAILURE; REPRODUCTIVE TOXICITY; REVIEW; BREAST NEOPLASMS; CHEMICALLY INDUCED; FEMALE; INFERTILITY, FEMALE; PATIENT SELECTION; PRIMARY OVARIAN INSUFFICIENCY; PROCEDURES; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; FERTILITY PRESERVATION; HUMANS; INFERTILITY, FEMALE; PATIENT SELECTION; PRIMARY OVARIAN INSUFFICIENCY; TREATMENT OUTCOME;

EID: 84908157874     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2014.05.024     Document Type: Review

References (81)

1. Surveillance, epidemiology, and end results program; . http://seer.cancer.gov/.
2. Azim H.A., Michiels S., Bedard P.L., Singhal S.K., Criscitiello C., Ignatiadis M., et al. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res 2012, 18(5):1341-1351.
3. Fredholm H., Eaker S., Frisell J., Holmberg L., Fredriksson I., Lindman H. Breast cancer in young women: poor survival despite intensive treatment. PloS ONE 2009, 4(11):e7695.
4. Cancello G., Maisonneuve P., Rotmensz N., Viale G., Mastropasqua M.G., Pruneri G., et al. Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Ann Oncol 2010, 21(10):1974-1981.
5. DeSantis C., Siegel R., Bandi P., Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin 2011, 61(6):409-418.
6. Rosen A., Rodriguez-Wallberg K.A., Rosenzweig L. Psychosocial distress in young cancer survivors. Semin Oncol Nurs 2009, 25(4):268-277.
7. Matthews T.J., Hamilton B.E. Delayed childbearing: more women are having their first child later in life. NCHS Data Brief 2009, 21:1-8.
8. Lee S.J., Schover L.R., Partridge A.H., Patrizio P., Wallace W.H., Hagerty K., et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. JClin Oncol 2006, 24(18):2917-2931.
9. Loren A.W., Mangu P.B., Beck L.N., Brennan L., Magdalinski A.J., Partridge A.H., et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. JClin Oncol 2013, 31(19):2500-2510.
10. Peccatori F.A., Azim H.A., Orecchia R., Hoekstra H.J., Pavlidis N., Kesic V., et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013, 24(Suppl.6):vi160-vi170.
11. Schmidt K.T., Larsen E.C., Andersen C.Y., Andersen A.N. Risk of ovarian failure and fertility preserving methods in girls and adolescents with a malignant disease. BJOG 2010, 117(2):163-174.
12. Mispelaere B., Van de Werf E., D'Hooghe T., Dieudonné A.-S., Amant F., Van Mieghem T., et al. Reproduction rates after cytotoxic therapy. JClin Oncol 2009, 27(27):e118-e119. [author reply e120].
13. Lambertini M., Anserini P., Levaggi A., Poggio F., Del Mastro L. Fertility counseling of young breast cancer patients. JThorac Dis 2013, 5(Suppl.1):S68-S80.
14. Faddy M.J., Gosden R.G., Gougeon A., Richardson S.J., Nelson J.F. Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reprod 1992, 7(10):1342-1346.
15. Munster P.N. Fertility preservation and breast cancer: a complex problem. Oncology (Williston Park) 2013, 27(6):533-539.
16. Lie Fong S., Laven J.S.E., Hakvoort-Cammel F.G.A.J., Schipper I., Visser J.A., Themmen A.P.N., et al. Assessment of ovarian reserve in adult childhood cancer survivors using anti-Müllerian hormone. Hum Reprod 2009, 24(4):982-990.
17. Bozza C., Puglisi F., Lambertini M., Osa E.-O., Manno M., Del Mastro L. Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients. Endocr Relat Cancer 2014, 21(1):R51-R65.
18. Visser J.A., de Jong F.H., Laven J.S.E., Themmen A.P.N. Anti-Müllerian hormone: a new marker for ovarian function. Reproduction 2006, 131(1):1-9.
19. Demeestere I., Moffa F., Peccatori F., Poirot C., Shalom-Paz E. Multiple approaches for individualized fertility protective therapy in cancer patients. Obstet Gynecol Int 2012, 2012:961232.
20. Okanami Y., Ito Y., Watanabe C., Iijima K., Iwase T., Tokudome N., et al. Incidence of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxane. Breast Cancer 2011, 18(3):182-188.
21. Oktem O., Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer 2007, 110(10):2222-2229.
22. Meirow D., Dor J., Kaufman B., Shrim A., Rabinovici J., Schiff E., et al. Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. Hum Reprod 2007, 22(6):1626-1633.
23. Kalich-Philosoph L., Roness H., Carmely A., Fishel-Bartal M., Ligumsky H., Paglin S., et al. Cyclophosphamide triggers follicle activation and burnout; AS101 prevents follicle loss and preserves fertility. Sci Transl Med 2013, 5(185):185ra62.
24. Azim H.A., Peccatori F.A., de Azambuja E., Piccart M.J. Motherhood after breast cancer: searching for la dolce vita. Expert Rev Anticancer Ther 2011, 11(2):287-298.
25. Azim H.A., Santoro L., Pavlidis N., Gelber S., Kroman N., Azim H., et al. Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. Eur J Cancer 2011, 47(1):74-83.
26. Sankila R., Heinävaara S., Hakulinen T. Survival of breast cancer patients after subsequent term pregnancy: «healthy mother effect». Am J Obstet Gynecol 1994, 170(3):818-823.
27. Azim H.A., Kroman N., Paesmans M., Gelber S., Rotmensz N., Ameye L., et al. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. JClin Oncol 2013, 31(1):73-79.
28. Cardoso F., Loibl S., Pagani O., Graziottin A., Panizza P., Martincich L., et al. The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Eur J Cancer 2012, 48(18):3355-3377.
29. Litton J.K. Breast cancer and fertility. Curr Treat Options Oncol 2012, 13(2):137-145.
30. Pagani O., Azim H. Pregnancy after breast cancer: myths and facts. Breast Care (Basel) 2012, 7(3):210-214.
31. Blakely L.J., Buzdar A.U., Lozada J.A., Shullaih S.A., Hoy E., Smith T.L., et al. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer 2004, 100(3):465-469.
32. Del Mastro L., Catzeddu T., Venturini M. Infertility and pregnancy after breast cancer: current knowledge and future perspectives. Cancer Treat Rev 2006, 32(6):417-422.
33. ISFP Practice Committee, Kim S.S., Donnez J., Barri P., Pellicer A., Patrizio P., et al. Recommendations for fertility preservation in patients with lymphoma, leukemia, and breast cancer. JAssist Reprod Genet 2012, 29(6):465-468.
34. Practice Committee of the American Society for Reproductive Medicine Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril 2013, 100(5):1214-1223.
35. Oktay K. Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing invitro fertilization to cryopreserve their embryos for fertility preservation. JClin Oncol 2005, 23(16):3858-3859.
36. Oktay K., Buyuk E., Libertella N., Akar M., Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. JClin Oncol 2005, 23(19):4347-4353.
37. Oktay K., Buyuk E., Davis O., Yermakova I., Veeck L., Rosenwaks Z. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod 2003, 18(1):90-95.
38. Azim A.A., Costantini-Ferrando M., Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. JClin Oncol 2008, 26(16):2630-2635.
39. Chung K., Donnez J., Ginsburg E., Meirow D. Emergency IVF versus ovarian tissue cryopreservation: decision making in fertility preservation for female cancer patients. Fertil Steril 2013, 99(6):1534-1542.
40. Jadoul P., Kim S.S., ISFP Practice Committee Fertility considerations in young women with hematological malignancies. JAssist Reprod Genet 2012, 29(6):479-487.
41. National Summary|Assisted Reproductive Technology (ART) Report|CDC reproductive health: . http://nccd.cdc.gov/DRH_ART/Apps/NationalSummaryReport.aspx.
42. Bianchi V., Lappi M., Bonu M.A., Borini A. Oocyte slow freezing using a 0.2-0.3 M sucrose concentration protocol: is it really the time to trash the cryopreservation machine?. Fertil Steril 2012, 97(5):1101-1107.
43. Rienzi L., Cobo A., Paffoni A., Scarduelli C., Capalbo A., Vajta G., et al. Consistent and predictable delivery rates after oocyte vitrification: an observational longitudinal cohort multicentric study. Hum Reprod 2012, 27(6):1606-1612.
44. Cao Y.-X., Chian R.-C. Fertility preservation with immature and invitro matured oocytes. Semin Reprod Med 2009, 27(6):456-464.
45. Fadini R., Dal Canto M.B., Mignini Renzini M., Brambillasca F., Comi R., Fumagalli D., et al. Effect of different gonadotrophin priming on IVM of oocytes from women with normal ovaries: a prospective randomized study. Reprod Biomed Online 2009, 19(3):343-351.
46. Donnez J., Jadoul P., Pirard C., Hutchings G., Demylle D., Squifflet J., et al. Live birth after transplantation of frozen-thawed ovarian tissue after bilateral oophorectomy for benign disease. Fertil Steril 2012, 98(3):720-725.
47. Demeestere I., Simon P., Moffa F., Delbaere A., Englert Y. Birth of a second healthy girl more than 3 years after cryopreserved ovarian graft. Hum Reprod 2010, 25(6):1590-1591.
48. Donnez J., Dolmans M.-M. Preservation of fertility in females with haematological malignancy. Br J Haematol 2011, 154(2):175-184.
49. Hubinont C., Debieve F., Biard J.M., Bernard P. Livebirth after cryopreserved ovarian tissue transplantation. Lancet 2012, 380(9837):106. [author reply 107; discussion 107-108].
50. Smitz J., Dolmans M.M., Donnez J., Fortune J.E., Hovatta O., Jewgenow K., et al. Current achievements and future research directions in ovarian tissue culture, invitro follicle development and transplantation: implications for fertility preservation. Hum Reprod Update 2010, 16(4):395-414.
51. Anderson R.A., Wallace W.H.B., Baird D.T. Ovarian cryopreservation for fertility preservation: indications and outcomes. Reproduction 2008, 136(6):681-689.
52. Rosendahl M., Andersen M.T., Ralfkiær E., Kjeldsen L., Andersen M.K., Andersen C.Y. Evidence of residual disease in cryopreserved ovarian cortex from female patients with leukemia. Fertil Steril 2010, 94(6):2186-2190.
53. Donnez J., Martinez-Madrid B., Jadoul P., Van Langendonckt A., Demylle D., Dolmans M.-M. Ovarian tissue cryopreservation and transplantation: a review. Hum Reprod Update 2006, 12(5):519-535.
54. Marhhom E., Cohen I. Fertility preservation options for women with malignancies. Obstet Gynecol Surv 2007, 62(1):58-72.
55. Chang H.J., Suh C.S. Fertility preservation for women with malignancies: current developments of cryopreservation. JGynecol Oncol 2008, 19(2):99-107.
56. Rivkees S.A., Crawford J.D. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA 1988, 259(14):2123-2125.
57. Del Mastro L., Giraudi S., Levaggi A., Pronzato P. Medical approaches to preservation of fertility in female cancer patients. Expert Opin Pharmacother 2011, 12(3):387-396.
58. Bokser L., Szende B., Schally A.V. Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats. Br J Cancer 1990, 61(6):861-865.
59. Ataya K.M., McKanna J.A., Weintraub A.M., Clark M.R., LeMaire W.J. Aluteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res 1985, 45(8):3651-3656.
60. Ataya K., Rao L.V., Lawrence E., Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995, 52(2):365-372.
61. Del Mastro L., Catzeddu T., Boni L., Bell C., Sertoli M.R., Bighin C., et al. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Ann Oncol 2006, 17(1):74-78.
62. Urruticoechea A., Arnedos M., Walsh G., Dowsett M., Smith I.E. Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC). Breast Cancer Res Treat 2008, 110(3):411-416.
63. Recchia F., Saggio G., Amiconi G., Di Blasio A., Cesta A., Candeloro G., et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 2006, 106(3):514-523.
64. Wong M., O'Neill S., Walsh G., Smith I.E. Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: menstruation and pregnancy outcomes. Ann Oncol 2013, 24(1):133-138.
65. Badawy A., Elnashar A., El-Ashry M., Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 2009, 91(3):694-697.
66. Del Mastro L., Boni L., Michelotti A., Gamucci T., Olmeo N., Gori S., et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 2011, 306(3):269-276.
67. Gerber B., von Minckwitz G., Stehle H., Reimer T., Felberbaum R., Maass N., et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. JClin Oncol 2011, 29(17):2334-2341.
68. Munster P.N., Moore A.P., Ismail-Khan R., Cox C.E., Lacevic M., Gross-King M., et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. JClin Oncol 2012, 30(5):533-538.
69. Sverrisdottir A., Nystedt M., Johansson H., Fornander T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 2009, 117(3):561-567.
70. Elgindy E.A., El-Haieg D.O., Khorshid O.M., Ismail E.I., Abdelgawad M., Sallam H.N., et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol 2013, 121(1):78-86.
71. Kim S.S., Lee J.R., Jee B.C., Suh C.S., Kim S.H., Ting A., et al. Use of hormonal protection for chemotherapy-induced gonadotoxicity. Clin Obstet Gynecol 2010, 53(4):740-752.
72. Bedaiwy M.A., Abou-Setta A.M., Desai N., Hurd W., Starks D., El-Nashar S.A., et al. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril 2011, 95(3):906-914.e1-e4.
73. Chen H., Li J., Cui T., Hu L. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev 2011, 11:CD008018.
74. Wang C., Chen M., Fu F., Huang M. Gonadotropin-releasing hormone analog cotreatment for the preservation of ovarian function during gonadotoxic chemotherapy for breast cancer: a meta-analysis. PloS ONE 2013, 8(6):e66360.
75. Yang B., Shi W., Yang J., Liu H., Zhao H., Li X., et al. Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a meta-analysis of randomized controlled trials. Breast Edinb Scotl 2013, 22(2):150-157.
76. Del Mastro L., Ceppi M., Poggio F., Bighin C., Peccatori F., Demeestere I., et al. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. Cancer Treat Rev 2014, 40(5):675-683.
77. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? the role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist 2007, 12(9):1044-1054.
78. Gurgan T., Salman C., Demirol A. Pregnancy and assisted reproduction techniques in men and women after cancer treatment. Placenta 2008, 29(Suppl.B):152-159.
79. Larsen E.C., Müller J., Schmiegelow K., Rechnitzer C., Andersen A.N. Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer. JClin Endocrinol Metab 2003, 88(11):5307-5314.
80. Ruddy K.J., Gelber S.I., Tamimi R.M., Ginsburg E.S., Schapira L., Come S.E., et al. Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol 2014, 32(11):1151-1156.
81. Snyder K.A., Pearse W. Discussing fertility preservation options with patients with cancer. JAMA 2011, 306(2):202-203.